Back to search

Peptide record

TPDB20274

Antibacterial Anticancer Hemolysis Toxicity standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB20274
Antibacterial Anticancer Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia PD_Hemolysis
standard
No
A 17-aa standard natural multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from Peptipedia and PD_Hemolysis, with an available 3D structural model.
Sequence
GLFDVIKKVASVIGPLG
Physicochemical Analysis
C81H137N19O21
RNCEQHMTWY
GV
1713.09
9.88
2
1
9
+1
0.99
1.112
148.82
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
1
A
0
R
0
N
1
D
0
C
0
E
0
Q
3
G
0
H
2
I
2
L
2
K
0
M
1
F
1
P
1
S
0
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 2 L: 2 K: 2 M: 0 F: 1 P: 1 S: 1 T: 0 W: 0 Y: 0 V: 3
Chemical Descriptors
17
C81H137N19O21
1713.09
9.88
+1
0.99
1.112
Evidence Records 8 records
Evidence 1 Activity

Activity

IC50
Toxicity
68.9 µM
Cytotoxic
IC50 | 68.9 | µM | target cell: Vero cells

Target

Vero cells

Source & Reference

NA
DBAASP
The design and anticancer activity of a citropin1.1 hybrid peptide with selective activity against highly invasive metastatic cell lines. | Int J Res Pharm Sci | 2019
Evidence 2 Activity

Activity

IC50
Toxicity
60.9 µM
Cytotoxic
IC50 | 60.9 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
The design and anticancer activity of a citropin1.1 hybrid peptide with selective activity against highly invasive metastatic cell lines. | Int J Res Pharm Sci | 2019
Evidence 3 Activity

Activity

88.6% Hemolysis
Toxicity
90 µM
Hemolytic Cytotoxic
88.6% Hemolysis | 90 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The design and anticancer activity of a citropin1.1 hybrid peptide with selective activity against highly invasive metastatic cell lines. | Int J Res Pharm Sci | 2019
Evidence 4 Activity

Activity

66% Hemolysis
Toxicity
70 µM
Hemolytic Cytotoxic
66% Hemolysis | 70 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The design and anticancer activity of a citropin1.1 hybrid peptide with selective activity against highly invasive metastatic cell lines. | Int J Res Pharm Sci | 2019
Evidence 5 Activity

Activity

39.5% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
39.5% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The design and anticancer activity of a citropin1.1 hybrid peptide with selective activity against highly invasive metastatic cell lines. | Int J Res Pharm Sci | 2019
Evidence 6 Activity

Activity

17.8% Hemolysis
Toxicity
30 µM
Hemolytic Cytotoxic
17.8% Hemolysis | 30 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The design and anticancer activity of a citropin1.1 hybrid peptide with selective activity against highly invasive metastatic cell lines. | Int J Res Pharm Sci | 2019
Evidence 7 Activity

Activity

13.1% Hemolysis
Toxicity
20
Hemolytic Cytotoxic
13.1% Hemolysis | 20 | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The design and anticancer activity of a citropin1.1 hybrid peptide with selective activity against highly invasive metastatic cell lines. | Int J Res Pharm Sci | 2019
Evidence 8 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis